CABA vs CAR: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CABA and CAR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CABA and CAR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Cabaletta Bio, Inc. (NASDAQ: CABA) is a clinical-stage biotechnology company focused on engineered T cell therapies for autoimmune disease. Its CABA (Cabaletta Approach to B cell Ablation) platform pursues the Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) approach, which uses CD19-directed CAR-T cells to deplete the B cells that drive autoimmune conditions, with the goal of a temporary but complete "immune system reset" rather than chronic suppression. The lead candidate, rese-cel (resecabtagene autoleucel, formerly CABA-201), is a fully human CD19-CAR T cell therapy.

Full CABA guide

Avis Budget Group runs one of the three big global vehicle-rental platforms, operating the Avis, Budget, Budget Truck, Payless and Zipcar brands across airport, off-airport, urban and international markets. Revenue comes from renting a large owned-and-leased vehicle fleet, and the economics hinge on utilization, per-day pricing and the residual value of cars when they are sold out of the fleet. The company competes with privately held Enterprise Holdings, Hertz, Europe's Sixt, and peer-to-peer platforms like Turo and Getaround.

Full CAR guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CABA drivers: Platform aimed at a large autoimmune market; Multi-indication RESET program.
• CAR drivers: Fleet utilization and pricing recovery; Vehicle residual values and fleet mix.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: CABA is a speculative, pre-revenue clinical-stage stock whose value depends on trial readouts that could fail, slip, or underwhelm. For CAR, the equity is small relative to enormous fleet and corporate debt, so modest swings in used-car residual values, interest rates or demand can move the stock sharply, and the shares carry a beta well above the market.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CABA if you believe its drivers more; CAR if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CABA and CAR guides.

CABA. Cabaletta is pre-profit and pre-revenue, so traditional metrics like price-to-earnings do not apply. Its value reflects the market's probability-weighted view of clinical success rather than current cash flow. Management has noted going-concern considerations, meaning the company expects to need additional capital to fund its longer-term plans.

CAR. CAR does not screen on a simple price-to-earnings basis because trailing earnings per share are negative, so investors lean on enterprise-value-to-EBITDA and the path back toward the company's roughly $1 billion adjusted EBITDA goal. With about 35 million shares outstanding and negative book equity, the stock behaves like a leveraged call on the rental cycle. Figures are approximate and drawn from the company's 2025 full-year and first-quarter 2026 disclosures.

Headline figures (approximate, June 27, 2026): CABA shows share price ~$3.04, market capitalization ~$496 million, cash, equivalents and short-term investments ~$116.6 million (as of March 31, 2026, before the May 2026 raise), 2026 financing ~$150 million registered direct offering closed May 2026 (~$141 million net proceeds); CAR shows revenue (fy2025) ~$11.7B, revenue (q1 2026) ~$2.53B, up ~4% YoY, net loss (fy2025) ~$995M, adjusted ebitda (fy2025) ~$748M.

CABA and CAR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CABA and CAR exposure against your real portfolio. It is not an investment adviser.